Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 2, 2004, Pages 770-777

  Hsu, Albert ^a   Togasaki, Daniel M ^a   Bezard, Erwan ^b   Sokoloff, Pierre ^c   Langsten, J William ^a   Di Monte, Donato A ^a   Quik, Maryka ^a  

^a PARKINSON S INSTITUTE   (United States)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BP 897; CARBIDOPA; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHOREOATHETOSIS; CONTROLLED STUDY; DENERVATION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; INVOLUNTARY MOVEMENT; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REGULATORY MECHANISM; SQUIRREL MONKEY;

ANIMALS; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DYSKINESIAS; FEMALE; PARKINSONIAN DISORDERS; PIPERAZINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SAIMIRI;

EID: 6344272628     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.071142     Document Type: Article

References (35)

1. Ahlskog JE and Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
2. Alexander GM, Schwartzman RJ, Brainard L, Gordon SW, and Grothusen JR (1992) Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res 588:261-269.
3. Ball J (2001) Current advances in Parkinson's disease. Trends Neurosci 24:367-369.
4. Bezard E, Brotchie JM, and Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-588.
5. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, and Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762-767.
6. Blanchet PJ, Allard P, Gregoire L, Tardif F, and Bedard PJ (1996) Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 23:189-193.
7. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, and Schwartz JC (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94:3363-3367.
8. Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Di Paolo T, and Bedard PJ (2000) Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47:870-78.
9. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, and Langston WJ (2000) Relationship among nigrostriatal denervation, parkinsonism and dyskinesias in the MPTP primate model. Mov Disord 15:459-466.
10. Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, and Quik M (2003) The D3 partial agonist BP897 attenuates dyskinesias in squirrel monkeys. Program No. 733.8. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2003. Online.
11. Hurley MJ, Stubbs CM, Jenner P, and Marsden CD (1996) D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 214:75-78.
12. Imbert C, Bezard E, Guitraud S, Boraud T, and Gross CE (2000) Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 86:71-76.
13. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, and Adler CH (2002) Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 955:138-152.
14. Langston JW, Quik M, Petzinger G, Jakowec M, and Di Monte DA (2000) Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 47:S79-S89.
15. Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
16. Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, and Sokoloff P (1992) Identification, characterization and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159.
17. Levesque D, Martres MP, Diaz J, Griffon N, Lammers CH, Sokoloff P, and Schwartz JC (1995) A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 92:1719-1723.
18. Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17 (Suppl 2):S32-S44.
19. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
20. Morissette M, Goulet M, Grondin R, Blanchet P, Bedard PJ, Di Paolo T, and Levesque D (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10:2565-2573.
21. Obeso JA, Olanow CW, and Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23:82-7.
22. Olanow CW and Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
23. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, and Sokoloff P (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature (Land) 400:371-375.
24. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, et al. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355-1366.
25. Quik M, Police S, He L, Di Monte DA, and Langston JW (2000) Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98:263-273.
26. Quik M, Police S, Langston JW, and Di Monte DA (2002) Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 113:213-220.
27. Quik M, Polonskaya Y, Kulak JM, and McIntosh JM (2001) Vulnerability of 1251-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey. J Neurosci 21:5494-5500.
28. Ryoo HL, Pierrotti D, and Joyce JN (1998) Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 13:788-797.
29. Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A, et al. (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275:1239-1246.
30. Schwartz JC, Diaz J, Bordet R, Griffon N, Perachon S, Pilon C, Ridray S, and Sokoloff P (1998) Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Res Brain Res Rev 26:236-242.
31. Sokoloff P, Andrieux M, Besancon R, Pilon C, Martres MP, Giros B, and Schwartz JC (1992) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol 225:331-337.
32. Sokoloff P, Giros B, Martres MP, Bouthenet ML, and Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (Lond) 347:146-151.
33. Tan LC, Protell PH, Langsten JW, and Togasaki DM (2002) The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord 17:902-909.
34. Tintner R and Jankovic J (2002) Treatment options for Parkinson's disease. Curr Opin Neurol 15:467-476.
35. Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, and Langston JW (2001) Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 50:254-257.